Verity Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Verity Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-7,267	Closed	-$311K	–	135
2019 Q3	$311K	Buy	7,267 +74	+1%	+$4.02K	0.33%	93
2019 Q2	$457K	Sell	7,193 -943	-12%	-$60K	0.51%	66
2019 Q1	$564K	Buy	8,136 +555	+7%	+$31.7K	0.65%	41
2018 Q4	$330K	Buy	7,581 +2,011	+36%	+$110K	0.44%	62
2018 Q3	$425K	Buy	5,570 +559	+11%	+$45.5K	0.42%	53
2018 Q2	$385K	Sell	5,011 -2,234	-31%	-$144K	0.35%	56
2018 Q1	$369K	Buy	7,245 +1,512	+26%	+$76.1K	0.34%	53
2017 Q4	$306K	Buy	+5,733	New	+$281K	0.23%	80

Other funds holding RARE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Verity Asset Management's RARE Position: Q4 2019 in Review

Verity Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2019, closing a stake of 7,267 shares — an estimated $311K sold.

Verity Asset Management first reported a position in RARE in Q4 2017 and held it in 8 quarters. The position peaked at $564K in Q1 2019. 172 funds tracked by Wall St. Rank hold RARE as of Q4 2019.

Verity Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2019 after selling out during the quarter.
Verity Asset Management sold 7,267 Ultragenyx Pharmaceutical shares in Q4 2019, an estimated $311K.
Verity Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and held it in 8 quarters.
Verity Asset Management's Ultragenyx Pharmaceutical position peaked at $564K in Q1 2019.
172 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2019.

Based on Verity Asset Management's 13F filing for Q4 2019, filed 11 Feb 2020.